Resveratrol and Pterostilbene Exhibit Anticancer Properties Involving the Downregulation of HPV Oncoprotein E6...

Post Reply
User avatar
Posts: 3871
Joined: Fri Mar 18, 2022 12:00 pm

Resveratrol and Pterostilbene Exhibit Anticancer Properties Involving the Downregulation of HPV Oncoprotein E6...

Post by TimGDixon »

Resveratrol and Pterostilbene Exhibit Anticancer Properties Involving the Downregulation of HPV Oncoprotein E6 in Cervical Cancer Cells

Chatterjee K, AlSharif D, Mazza C, Syar P, Al Sharif M, Fata JE,.
Author information

PMID: 29485619 PMCID: PMC5852819 DOI: 10.3390/nu10020243

Cervical cancer is one of the most common cancers in women living in developing countries. Due to a lack of affordable effective therapy, research into alternative anticancer compounds with low toxicity such as dietary polyphenols has continued. Our aim is to determine whether two structurally similar plant polyphenols, resveratrol and pterostilbene, exhibit anticancer and anti-HPV (Human papillomavirus) activity against cervical cancer cells. To determine anticancer activity, extensive in vitro analyses were performed. Anti-HPV activity, through measuring E6 protein levels, subsequent downstream p53 effects, and caspase-3 activation, were studied to understand a possible mechanism of action. Both polyphenols are effective agents in targeting cervical cancer cells, having low IC50 values in the µM range. They decrease clonogenic survival, reduce cell migration, arrest cells at the S-phase, and reduce the number of mitotic cells. These findings were significant, with pterostilbene often being more effective than resveratrol. Resveratrol and to a greater extent pterostilbene downregulates the HPV oncoprotein E6, induces caspase-3 activation, and upregulates p53 protein levels. Results point to a mechanism that may involve the downregulation of the HPV E6 oncoprotein, activation of apoptotic pathways, and re-establishment of functional p53 protein, with pterostilbene showing greater efficacy than resveratrol.

Figure 1: Pterostilbene is more potent in eliminating HeLa cervical cancer cells as compared to resveratrol: (A) Brightfield analysis of HeLa cells untreated (Ai) or treated for 24 h with 40 µM of resveratrol (Res; Aii) or 40 µM of pterostilbene (Pte; Aiii). Evidence of cell elimination was only seen robustly in cells treated with pterostilbene at 40 µM. (B) Analysis of IC50 values, generated by a Water Soluble Tetrazolium salt-1 (WST-1) assay after 24 h of exposure to resveratrol or pterostilbene indicates that pterostilbene (IC50 = 42.3 µM) is a more potent cytotoxic agent than resveratrol (IC50 = 83.5 µM; Bii). The graphs represent data from three independent experiments (mean ± S.E.M. (Standard error mean)). (C) Clonogenic assays performed to compare the relative effect of the two polyphenols on the clonogenicity of HeLa cells untreated (Ci) or treated with 50 µM of either resveratrol (Cii) or pterostilbene (Ciii). Results are from 15-days post-treatment and indicate that pterostilbene is more efficient in curbing the clonogenicity compared to resveratrol (Civ). Bar graph represents data from three independent experiments (mean ± S.E.M.; * p < 0.05; Civ).

fig1.jpg (527.29 KiB) Viewed 598 times

Pterostilbene Is More Potent in Eliminating HPV+ HeLa Cells Compared to Resveratrol

In order to study the comparative cytotoxicity of pterostilbene and resveratrol on HeLa tumor cells, brightfield images (Figure 1A) and WST-1 cell viability assays (Figure 1B) were performed 24 h post-treatment. The brightfield images taken after 24 h of treatment (Figure 1A) showed that pterostilbene (40 µM) eliminates significantly more cells than resveratrol at the same concentration. Live imaging of cells treated with 60 µM of the two compounds show significantly more death and characteristic apoptotic blebbing in pterostilbene-treated cells when compared to untreated or resveratrol-treated cells (Supplementary Videos S1–S3). The WST-1 analysis revealed that although both pterostilbene and resveratrol eliminated HeLa cells significantly and in a dose-dependent manner, pterostilbene displayed a 1.97-fold lower IC50 when compared to resveratrol (42.3 µM vs. 83.5 µM; p < 0.05; Figure 1B). Additionally, both compounds, at 50 µM, significantly inhibited the clonogenicity of post-treated cells in a 15-day clonogenic assay (Figure 1C). Pterostilbene significantly reduced clonogenic survival by 87.5% compared to the control (p < 0.05), while resveratrol inhibited it by 63% (p < 0.05) (Figure 1C). Moreover, the difference between the survival percentages of the two treatment groups is significant (p < 0.05).

Live imaging of cells treated with 60 µM of pterostilbene (S3).

Of the two compounds, pterostilbene showed significantly more death and characteristic apoptotic blebbing with the pterostilbene-treated cells than when compared to untreated or resveratrol-treated cells.

Inhibition of Cell Migration of HeLa Cells Treated with Pterostilbene and Resveratrol

To determine the comparative efficacy of resveratrol and pterostilbene in inhibiting HeLa cell migration, two different sub-lethal concentrations of each compound were used in a 48-h scratch assay (Figure 2). Based on the WST-1 results and brightfield images (unpublished), we found that cells treated with a concentration below 25 µM showed no signs of cellular toxicity. To avoid any cytotoxicity, we used lower concentrations of 5 µM and 20 µM. At sub-lethal concentrations of 5 µM and 20 µM, both resveratrol and pterostilbene significantly inhibited HeLa cell migration relative to untreated cells (p < 0.05; Figure 2). Pterostilbene was more effective in inhibiting HeLa cell migration at 20 µM when compared to resveratrol; however, this result was not significantand no differences were seen between the two compounds at 5 µM (Figure 2). In an effort to analyze the effects of resveratrol and pterostilbene on cell migration, we normalized the amount of migration into the scratch (wound) by untreated cells, to 100%. Relative to this control, resveratrol-treated cells migrated only 71.2% (5 µM) and 63.7% (20 µM), while cells treated with pterostilbene migrated only 69.5% (5 µM) and 49.2% (20 µM) (Figure 2).

Figure 2: Resveratrol and pterostilbene inhibit cell migration: (A) HeLa cells were monitored for cell migration into a scratched “wound”. Cells were either untreated or treated with sub-lethal concentrations (5 µM and 20 µM) of resveratrol (Res) or pterostilbene (Pte). The extent of migration into the scratched area was calculated after 48 h and revealed that both resveratrol and pterostilbene significantly inhibit cell migration, although pterostilbene had greater anti-migratory effect. (B) The graphs represents data from triplicate sample experiments normalized to the control (mean % migrated cells ± S.E.M.; * p < 0.05). Scale bar: 0.05 µm.

fig2.jpg (354.25 KiB) Viewed 598 times

Cell Cycle Arrest at S-Phase in HeLa Cells Treated with Low Concentrations of Resveratrol and Pterostilbene

In order to compare the effect of sub-lethal doses of either resveratrol or pterostilbene on the cell cycle of HeLa cells, treatment was carried out with three different concentrations (5 µM, 10 µM, and 15 µM) of the two compounds for 18 h prior to flow cytometric analysis (Figure 3A). Flow cytometry analysis showed that the cells treated with either compound exhibited a significant decrease in the number of cells in the G2-M phase with respect to the control cells (p < 0.05) (Figure 3A,B, Table 1), indicating an S-phase cell cycle arrest. This effect corresponded with an increase in the number of cells arrested at the S-phase. Pterostilbene was significantly more potent than resveratrol in inhibiting cell cycle progression, showing effects at concentrations as low as 5 µM (p < 0.05) (Figure 3A,B, Table 1). At this concentration, pterostilbene had these percentages of cells in each phase: G1 = 53.4 ± 1.4, S = 34 ± 1.4, G2 =12.5 ± 0.2, while resveratrol had values of G1 = 64.8 ± 2.0, S = 16.3 ± 1.0, G2 = 18.3 ± 2.3. At a higher concentration (15 µM) both compounds significantly inhibited cells from entering into G2-M by arresting them in the S-phase, and difference between the extent of the arrest at this phase induced by the two compounds was significant (p < 0.05) (Figure 3A,B, Table 1).

Figure 3: S-phase arrest in HeLa cells treated with low concentrations of resveratrol and pterostilbene: (A) Flow-cytometric evaluation of HeLa cells untreated or treated with sub-lethal doses of resveratrol (Res) and pterostilbene (Pte) for 18 h. Treated cells exhibited S-phase arrest and a subsequent decrease in the number of cells in G2/M. Pterostilbene was a more potent compound than resveratrol, showing a capacity to arrest cells at the S-phase at concentrations as low as 5 µM. (B) Graphical representation of the dose-dependent cell cycle effects induced by resveratrol and pterostilbene at three different concentrations (5 µM, 10 µM, and 15 µM). (B) The graph represents data from triplicate sample experiments normalized to the control (mean % cells in each phase ± S.E.M.) (C) Immunofluorescent images of HeLa cells probed for the M-phase marker phospho-histone-H3 (serine10). HeLa cells were untreated or treated with 5 µM and 10 µM of resveratrol or pterostilbene. Immunofluorescent images display a decrease of histone-H3 in cells treated with both the compounds, the effects at 5 µM of pterostilbene is much greater than those of resveratrol (at 5 µM). (D) Graphical representation of the percent of mitotic cells calculated from immunofluorescent images reveal that resveratrol and to a greater extent pterostilbene are effective in decreasing the number of mitotic HeLa cells. The graph represents data from experiments obtained from triplicate samples normalized to the control (mean % mitotic cells ± S.E.M.;* p < 0.05).

fig3.jpg (557.17 KiB) Viewed 598 times

Downregulation of Viral Oncoprotein E6 and Upregulation of Active-Caspase-3 in HeLa Cells Treated with Pterostilbene and Resveratrol

In order to investigate how resveratrol and pterostilbene were affecting HeLa cell survival and cell cycle progression, we treated cells with either of the two compounds at sub-lethal (10 µM) and higher (50 µM) concentrations prior to analysis by immunostaining for E6, active caspase-3, and p53 (Figure 4A–C). At 10 µM, both resveratrol and pterostilbene failed to significantly affect levels of E6 and active caspase-3 levels relative to the control (Figure 4A,B). However, at 50 µM both compounds significantly suppressed E6 levels and elevated cleaved caspase-3 levels in treated cells relative to the untreated cells (Figure 3A–C). At this concentration (50 µM), pterostilbene was significantly more potent than resveratrol at suppressing E6 levels (resveratrol = 0.77 ± 0.11: 23% decrease vs. pterostilbene = 0.57 ± 0.06: 43% decrease; p < 0.05) and simultaneously elevating active caspase-3. It should be noted that we were unable to detect any noticeable differences in the sub-cellular localization of E6 in treated cells (Figure 4A).

Figure 4: Downregulation of viral oncoprotein E6 and upregulation of active-caspase-3 in HeLa cells treated with resveratrol or pterostilbene: (A) HeLa cells immunostained for E6 levels (green) and counterstained with the nuclear dye 4’,6-diamidino-2-phenylindole (DAPI) (blue) after treatment with resveratrol (Res) and pterostilbene (Pte; 10 µM and 50 µM). Loss of E6 proteins are visually evident in cells treated with 50 µM of either resveratrol or pterostilbene. (B) Cell image analysis of the E6 fluorescent data revealed a significant 43% decrease of E6 protein levels in HeLa cells treated with pterostilbene at 50 µM and a 23% decrease of E6 levels in cells treated with resveratrol, both relative to the control. The graph represents data from experiments obtained from three independent experiments normalized to the control (mean % normalized to DAPI ± S.E.M.; * p < 0.05). (C) Immunofluorescent images probing for active-caspase-3 (green) shows a corresponding enhanced activation of this mediator of apoptosis by both resveratrol and pterostilbene.

fig4.jpg (693.66 KiB) Viewed 598 times

Upregulation of Tumor Suppressor Protein p53 in HeLa Cells Treated with Pterostilbene and Resveratrol

Concomitant with E6 suppression, 50 µM pterostilbene treatment for 22 h caused an upregulation of p53 in HeLa cells (Figure 5A,B). When compared to the control, pterostilbene treatment elicited a 2-fold increase in p53 levels (staining normalized to DAPI; Figure 5B; p < 0.05). In comparison to the control, HeLa cells treated with 50 µM of resveratrol also caused an upregulation of p53 (1.75-fold increase; Figure 5A,B; p < 0.05) at 22 h.

fig5.jpg (468.22 KiB) Viewed 598 times


Cervical cancer is a major concern in developing countries due to lack of affordable prophylaxis and treatment. As present modes of treatment like surgery, chemotherapy, or radiation involve high systemic toxicity, there is an urgent need to find affordable alternative therapies. Diet-based polyphenols like resveratrol and pterostilbene are therefore potential candidates for the effective therapy of cervical cancer with significantly low toxicity. We found pterostilbene to be a more potent anticancer agent than resveratrol in HeLa cells. This difference may be a function of pterostilbene being capable of upregulating p53 and downregulating E6 significantly more than resveratrol. As pterostilbene is non-toxic to normal cells [20], it has the potential to be a robust, cost-effective anti-E6+ tumor drug. Others have found that that pterostilbene possess greater bioavailability and stability [45] than resveratrol in vivo (80% vs. 20%). Resveratrol has been shown to be non-toxic to several cells lines like glial cells and neurons, even after a treatment dose of 100 µM for 48 h [46]. Other studies on normal fibroblasts also state the non-toxicity of resveratrol at our observed potent anticancer concentrations [47]. Additionally, pterostilbene shows no toxicity at these concentrations in normal skin fibroblasts and myoblasts [48]. According to clinical studies, the safe dosage for resveratrol and pterostilbene is 5 g/day [49] and 250 mg/day [20], respectively. Our initial in vivo studies in the laboratory using a non-toxic dosage of both resveratrol and pterostilbene has shown promising results in inhibiting tumor growth in a model of cervical cancer [32]. Taken together, our findings support the further evaluation of pterostilbene as a possible therapy against cervical cancer.

Here, we show that pterostilbene potently suppresses HPV E6 expression (Figure 4) and efficiently eliminates HPV+ cells in culture by p53-mediated apoptosis (Figure 1 and Figure 5) while suppressing cell proliferation (Figure 3) and migration (Figure 2). We find that pterostilbene is a more promising agent against cervical cancer when compared to resveratrol. Based on such properties, the use of pterostilbene presents a relatively economical but highly hopeful therapeutic approach to treat HPV infections and cervical cancers. Our future studies will include signaling studies using HPV+ murine tumor models to confirm these observations in vivo.
“And the corner sign says it's closing time so I'll bid farewell and be down the road...”
Posts: 564
Joined: Sat Mar 19, 2022 10:10 am

Natural Bioactive Compounds Targeting Histone Deacetylases in Human Cancers: Recent Updates

Post by curncman »

Natural Bioactive Compounds Targeting Histone Deacetylases
in Human Cancers: Recent Updates
Pterostilbene treats cancer
(1.3 MiB) Downloaded 23 times
I am well wisher of everyone! GOD will pardon all your sins but not your Central Nervous System! Think Positive!
Posts: 564
Joined: Sat Mar 19, 2022 10:10 am

Natural Compounds That Target DNA Repair Pathways and Their Therapeutic Potential to Counteract Cancer Cells

Post by curncman »

Natural Compounds That Target DNA Repair Pathways and Their Therapeutic Potential to Counteract Cancer Cells ... 98174/full

Department of Genetics and Molecular Biology, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV), Mexico City, Mexico
Resistance to current cancer treatments is an important problem that arises through various mechanisms, but one that stands out involves an overexpression of several factors associated with DNA repair. To counteract this type of resistance, different drugs have been developed to affect one or more DNA repair pathways, therefore, to test different compounds of natural origin that have been shown to induce cell death in cancer cells is paramount. Since natural compounds target components of the DNA repair pathways, they have been shown to promote cancer cells to be resensitized to current treatments. For this and other reasons, natural compounds have aroused great curiosity and several research projects are being developed around the world to establish combined treatments between them and radio or chemotherapy. In this work, we summarize the effects of different natural compounds on the DNA repair mechanisms of cancer cells and emphasize their possible application to re-sensitize these cells.

Day by day we are exposed to chemical carcinogens in the environment, ultraviolet (UV) radiation, ionizing radiation, and also those substances produced in our body during cellular metabolism that attack and produce a variety of DNA injuries. Each lesion favors the development of alterations in DNA and chromosomes, which favors oncogenic transformation and tumor progression. In order to reduce the number of changes in the genome and its instability, cells have several pathways of response to damage and DNA repair proteins that eliminate these lesions (1). DNA adducts, such as those created by alkylating agents, can be cleaved and repaired by base excision repair (BER) or by nucleotide excision repair (NER), depending on whether it is necessary to remove only a nitrogenous base or a nucleotide (2). Also, O-6-methylguanine-DNA methyltransferase (MGMT), an alkyltransferase, eliminates alkylations (3). Mismatch repair (MMR) is a system for repairing the insertion, deletion, and misincorporation of bases that can arise during DNA replication and recombination. While, direct double-strand breaks are repaired by non-homologous end joining, those associated with replication are repaired by homologous recombination. Other repair pathways active during replication include the Fanconi anemia repair pathway, endonuclease-mediated repair, and RecQ-mediated repair (2, 4).

Several cancer cells in contrast to normal cells have one or more DNA repair pathways defective during carcinogenesis, leading to a greater reliance on the remaining pathways and at the same time accumulating mutations during the process (5). Examples of these are the silencing of MGMT in approximately 40% of glioblastomas (6) and the downregulation of MMR genes in colon cancer (7, 8). However, some types of cancer overexpress DNA repair genes and this makes them more resistant to the treatments currently used, causing what is known as resistance (9). Resistance to current cancer treatments is a major problem that requires the search for new compounds that can re-sensitize cancer cells. We speak of resistance when a cancer cell develops the ability to resist radio and chemotherapy, and this can be achieved through various mechanisms such as regulation of the entry and exit of drugs, inhibition of cell death, alterations in metabolism and degradation of drugs, epigenetic factors, and improved DNA repair (10). In terms of its effects on DNA repair, DNA repair inhibitors have been shown to increase the efficacy of anticancer drugs and several works have illustrated the sensitizing efficacy of natural compounds in various cancers (11). Natural compounds are biologically active substances present in plants, fungi, bacteria, and other organisms that affect DNA repair, and are classified mainly according to their chemical structure into terpenes, carotenoids, phenolic compounds (Table 1): phenolic acids, flavonoids, stilbenes, coumarins, tannins; alkaloids, nitrogen compounds; organosulfates: isothiocyanates and indoles, allyl sulfates. Flavonoids are further divided into chalcones, flavanones, flavones, flavonols, flavanols, isoflavones, and anthocyanins (12). In this work, we summarize the effects of different natural compounds on the DNA repair mechanisms of cancer cells and emphasize their possible application to re-sensitize these cells to radio and chemotherapy (Figure 1).

Resveratrol is a natural polyphenolic compound, specifically a stilbene, which is found in significant amounts in grapes, berries, peanuts, and other plant sources, as well as in red wine. This compound has become very popular due to its multiple reported properties that include inflammation-mediating, cardioprotective, antioxidant, and anti-cancer, among other things (13). As an anti-cancer compound, low-dose resveratrol accelerates non-mutagenic repair of DNA damage in mouse embryonic stem cells exposed to ionizing radiation (14). Similarly, resveratrol in mouse embryonic fibroblasts was shown to help maintain genomic stability after chemical and ionizing radiation damage by allowing greater repair efficiency of double-strand breaks and less replicative stress (15). Furthermore, resveratrol was shown to significantly reduce DNA damage from arsenic compounds in non-cancerous mammalian cells by enhancing repair activities, especially if used prior to exposure (16). Resveratrol causes DNA damage and activates the repair mechanisms in various cancer cell lines such as prostate cancer cells, colon cancer cells, and breast cancer cells (17, 18). Indeed, head and neck squamous cell carcinoma cells as well as breast cancer cells receive more DNA damage than their normal counterparts (19, 20). Non-small cell lung cancer cells have shown DNA damage after treatment with resveratrol, which was potentiated by the pemetrexed antifolate that destabilizes ERCC1 protein, an essential nuclease in the BER pathway and, to a lesser extent, in double-stranded DNA breaks and in crosslink repair, by inhibiting p38 MAPK activity (21). Resveratrol has been shown to affect different DNA repair pathways in MCF7 breast cancer cells by reducing the expression of several genes involved in this activity and where mismatch repair and homologous recombination stand out such as most affected (22). Resveratrol made breast cancer cells more susceptible to cisplatin, and specifically in cisplatin-resistant MCF7 cells, resveratrol was able to re-sensitize cells by decreasing several key components of the homologous recombination pathway (23). Etoposide in combination with resveratrol treatments were more effective than either chemical alone given as treatment to stop cell proliferation and eliminate non-small-cell lung cancer cells by suppressing the expression of the XRCC1 protein (DNA repair protein within NER or BER pathway) (24). The same happened in sphere cultures of cervical cancer cells treated with this combination, but in this case a strong decrease in the expression of the RAD51 protein (DNA repair protein within HR pathway) was reported (25). Resveratrol potentiates the effects of temozolomide on glioblastoma cells by negatively regulating the NF-κB pathway and thereby causing a reduction in MGMT expression (26). Resveratrol switched radioresistant prostate cancer cells back to sensitive phenotype by inhibiting ATM phosphorylation and its target protein H2AX, causing cell cycle arrest and subsequently cell death (27). Resveratrol also radiosensitized glioma stem cells by causing an accumulation of DNA damage that impairs their self-renewal and potency (28). By the same mechanism, resveratrol together with capsaicin made radiosensitive pancreatic tumor cells more susceptible to the effect of radiation (29). In colon cancer cells resistant to 5-fluorouracil, resveratrol in conjunction with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) managed to induce apoptosis and re-sensitize the cells by decreasing the levels of FEN1 and PCNA (30). The same decrease in both proteins was observed in cigarette smoke-induced breast cancer cells treated with resveratrol alone, where it was also detailed that p21 levels increased and affected the binding of FEN1 to PCNA, thus inhibiting the long patch base excision repair pathway. Other components of this pathway, such as DNA-ligase-I and polymerases (β, δ, ϵ) were also decreased (31). Despite the fact that melanoma cells have an increased expression of APE/REF1, especially those resistant to dacarbazine, it has been shown that resveratrol can sensitize them by inhibiting REF1-activated AP-1 DNA bindings (32). As can be seen from the data referred, resveratrol is an important candidate despite somewhat solubility issues that affect its bioavailability.

Curcumin is a bright yellow hydrophobic polyphenol present in the rhizome of turmeric (Curcuma longa) and to which antimicrobial, anti-inflammatory, antioxidant, immunomodulatory, renoprotective, hepatoprotective, hypoglycemic, and anti-cancer effects have been attributed (33). Curcumin’s ability to affect multiple pathways makes it an extremely powerful anticancer agent. Furthermore, curcumin has shown multiple effects on DNA repair systems, both in healthy cells and cancer cells. Curcumin prevents DNA damage in lymphocytes of people chronically exposed to arsenic and improves its repair capacity. Thus, it induces an increase in the proteins of the base excision repair and non-homologous end joining pathways and collaborates to avoid carcinogenesis (34). Also, in murine models, curcumin reduced cyclobutane and pyrimidine dimers produced after exposure to UVB radiation and delayed skin carcinogenesis (35). In cancer cells, curcumin blocks both non-homologous end joining and homologous recombination pathways: by inhibiting the acetyltransferase activity of CBP on histone at double strand breaks thus preventing the recruitment of KU70/KU80 proteins and p300 on BRCA1 promoter and causing downregulation of its expression. ATR kinase activity is also inhibited by curcumin, causing cell cycle arrest in the G2 phase (36, 37). It has also been seen that mismatch repair is important in curcumin activity because cells deficient in this system, particularly when MSH2 and MLH1 proteins are affected, show a greater sensitivity to it. The difference is that the competent cells of the mismatch repair system can activate CHK1 and arrest in the G2/M phase before inducing apoptosis, whereas the deficient cells go directly to apoptosis (38). In gastric cancer cells, curcumin induces DNA damage that is reflected by overexpression of DNA-PKcs, ATM, ATR, HDAC1, p21, and GADD45A along with activation of the p53 pathway, which consequently suppresses phosphorylation of Rb and expression of cyclin E, thus stopping the cell cycle and causing a general demethylation of DNA by repressing the expression of DNMT1 thus allowing the re-expression of tumor suppressor genes (39). The same effect on DNMT1 was reported in curcumin-treated breast cancer cells, but the effects were different between cell lines. For example, in HCC-38 cells, the curcumin-dependent decrease in DNMT1 together with the inhibition of miR-29b caused an increase in TET1 (a methylcytosine dioxygenase that plays an important role in the demethylation of DNA) allowing BRCA1 re-expression, but this did not occur in T47D cells (40). It is also important to note that the response to DNA damage triggered by curcumin and varies according to the BRCA1 mutation status in triple negative breast cancer cells, but regardless of this, in all cases it leads to apoptosis (41). In curcumin-treated MCF-7 breast cancer cells, a decrease in FEN1 (long patch BER pathway) was observed as a result of overexpression of NRF2 and its positioning on the promoter of this gene, thus collaborating to prevent cell proliferation (42). In lung cancer cells, curcumin reduces the levels of some DNA repair proteins such as BRCA1, MGMT, MDC1, and 14-3-3σ, but elevates DNA damage proteins such as phosphorylated p53 and γH2AX, thus causing cytotoxicity, condensation of the nucleus, and DNA damage (43). Meanwhile, curcumin causes DNA damage in cervical cancer cells and increases levels of BRCA1, MGMT, MDC1, p53, DNA-PKcs, MDM2, PARP, and the phosphorylated forms of ATM, ATR, and H2AX (44). In contrast, RAD51 foci formation was also decreased in lymphoma cells and breast cancer cells treated with curcumin (45, 46).

On the other hand, the ability of curcumin to reverse chemoresistance in various cancers is remarkable. In combination with cisplatin, curcumin prevents the activation of p38 MAPK through MKP1 phosphatase activity consequently affecting the expression of XRCC1, making lung cancer cells more sensitive to the cytotoxic effects of this chemotherapeutic agent (47). A decrease in thymidine phosphorylase, ERCC1 and RAD51 can also be observed with this combination and with mitomycin C and curcumin, which is due to the inhibition of ERK1/2 activity and an increase in their ubiquitin-mediated 26S proteasome degradation (48, 49). As a complementary medicine to carboplatin, curcumin reduces its adverse effects by selectively activating nucleotide excision repair and homologous recombination in bone marrow cells through positive regulation of BRCA1, BRCA2, and ERCC1 expression, but it has the opposite effect on malignant cells (50). Together with quinacrine, curcumin binds DNA more efficiently, being able to cause further damage to breast cancer stem cells and preventing their repair by lowering the expression of DDB2, Polβ, Polδ, PolH, Rad51, Fen1, XRCC1, CHK1, and RPA proteins (51). Curcumin increases the apoptotic effects of cisplatin on cisplatin-resistant lung adenocarcinoma cells by inhibiting FANCD2 monoubiquitination and, therefore, also preventing activation of the Fanconi anemia/BRCA pathway that enables DNA repair by homologous recombination (52). The same effect was reported in multiple myeloma cells treated with melphalan and curcumin (53). Curcumin sensitizes colon cancer cells to radiation by modifying the expression of several genes, highlighting an overexpression of CCNH and XRCC5 along with low expression of LIG4 and PNKP (54). Hydroxyurea, camptothecin, and cisplatin were shown to be more efficient in lymphoma cells when combined with curcumin (45). In the same way, PARP inhibitors and DNA-PK inhibitors together with curcumin showed a synergistic effect to induce DNA damage, apoptosis, and mitotic cell catastrophe in different cancer cell lines (36, 45, 46). This, in part, due to the inhibition of topoisomerase II and the reduction in the expression of WRN, FEN1, APE1, DNA ligase III, and XRCC1 (55).

The main polyphenolic component of green tea (Camellia sinensis) extracts is epigallocatechin gallate (EGCG), an ester of epigallocatechin and gallic acid, and a type of catechin. Biological effects that have been reported for EGCG are antioxidant, anti-inflammatory, neuroprotective, cardioprotective, and anti-cancer (56). In terms of anti-cancer effects, among the many activities that EGCG has (57), some of them are related to its effect on DNA repair systems. EGCG is a compound capable of inhibiting the activity of the ERCC1/XPF protein in non-small cell lung cancer cell lines, blocking the intrastrand crosslink repair, and thus enhancing the cytotoxic activities of cisplatin, preventing proliferation and increasing cellular death (58). Furthermore, EGCG selectively decreased MGMT levels in glioblastoma multiforme cells by preventing translocation of β-catenin to the nucleus, thereby avoiding the removal of temozolomide-produced O6-methylguanine and helping to resensitize cells resistant to this drug. In contrast, EGCG improved MGMT expression in non-tumor glial cells by inhibiting DNMT1 and allowing demethylation of its promoter (59). Normal human leucocytes with continuous low-dose EGCG treatments show less DNA damage (single and double chain mutations, adducts, and mutations) when exposed to genotoxic agents such as bleomycin and some heterocyclic amines (60, 61).

Triptolide is a diterpene triepoxide obtained from the Chinese medicinal plant Tripterygium wilfordii Hook F, commonly known as lei gong teng or thunder god vine. This compound has a variety of bioactivities and pharmacological effects such as anti-microbial, anti-inflammatory, neuroprotective, cardiovascular, immunosuppressive, and recently anti-cancer (62). The anticancer effects of triptolide are time and dose dependent, varying according to cell type, but where its effects on DNA repair mechanisms stand out, most often culminating in apoptosis of cells. First, triptolide was shown to affect the nucleotide excision repair pathway by selectively inhibiting the ATPase activity of XPB helicase, thus allowing for a malfunction of the TFIIH holocomplex and preventing filling of the gaps after damage excision (63). Then, triptolide was reported to inhibit the double-stranded DNA damage response in breast cancer cells through post-transcriptional downregulation of ATM, which causes a reduction in the levels of γH2AX (64). The same was observed in melanoma cell lines along with decreased levels of ATR, BRCA-1, DNA-PKcs, MGMT, and p53 (65). Meanwhile, in murine B−cell lymphoma cells and acute lymphoblastic leukemia cells, triptolide induces DNA double strand breaks with upregulation of γH2AX and RAD51, which culminates in caspase-3 dependent apoptosis and helps enhance the effects of PARP1 and PI3K inhibitors, as well as re-sensitizing cytarabine- and doxorubicin-resistant leukemia cells (66, 67). Triptolide was shown to cause a decrease in the levels of PARP1, XRCC1, and RAD51 proteins in triple negative breast cancer cells, affecting single-strand break repair, base excision repair, and homologous recombination pathways (64). Furthermore, this natural compound causes cells accumulate DNA damage, stopping their growth, and being arrested in the S phase of the cell cycle, as well as presenting a greater sensitivity to chemotherapeutic agents such as cisplatin and doxorubicin (64, 68). Lung cancer cells showed an increase in ATM phosphorylation after combined treatment of cisplatin with triptolide, which led to the activation of apoptotic genes such as PUMA (69). Likewise, triptolide showed synergy with oxaliplatin in pancreatic cancer cell lines by producing a decrease in the expression of key proteins in the nucleotide excision repair pathway such as XPA, XPB, XPC, ERCC1, XPD, and XPF, but unlike breast cancer cells, here showing an increase in the levels of γH2AX and, therefore, also of DNA double strand breaks (70).

Quercetin is a flavonoid found in a variety of foods, including fruits and vegetables such as apples, berries, capers, grapes, onions, shallots, tea, and tomatoes, as well as many seeds such as nuts, flowers, bark, and leaves (71). Quercetin is known for its anti-inflammatory, antihypertensive, vasodilatory, anti-hypercholesterolemic, anti-atherosclerotic, antioxidant and, more recently, anti-cancer effects (72). Quercetin following a 1,2-dimethylhydrazine dihydrochloride (DMD) induced colon carcinogenesis protocol allowed decreased production of 8-oxoguanine and apurine/pyrimidine sites by increasing levels of the BER proteins OGG1, APE1, and XRCC1, and positively modulate NRF2 signaling with a higher antioxidant response (73). Also in response to oxidative damage to colon cells by H2O2, an increase in OGG1 was observed (74). In prostate cancer cells, quercetin significantly reduced the expression of ATM, PARP1, and DNA-PKcs (75). Quercetin suppresses the repair of double-stranded DNA breaks and improves the radiosensitivity of ovarian cancer cells through activation of ATM and the p53-dependent endoplasmic reticulum stress pathway (76). Meanwhile, in some colorectal cancer, cervical cancer and breast cancer cell lines, quercetin acted as a radiosensitizer by blocking ATM activation and its downstream signaling, thereby prolonging the persistence of damage and inducing apoptosis (77). Quercetin can potentiate the effects of PARP inhibitors, preventing efficient repair of DNA damage, and where inhibition of BRCA2 activity plays an important role during the passage of single-strand breaks to double-strand breaks during DNA replication (78).

Berberine is an isoquinoline alkaloid isolated mainly from the Chinese herb Coptis chinensis, although it is also present in other plants of the genus Berberis. It has a wide range of pharmacological properties such as anti-inflammatory, antibiotic, antitumor, antiarrhythmic functions, and it can regulate blood lipids and glucose levels (79). Berberine has been shown to induce oxidative DNA damage and alter RAD51 expression in ovarian cancer cells, breast cancer cells, and osteosarcoma cells, but not in normal cells, thereby causing increased DNA damage and longer, with abundant γH2AX, ATM, and p53 foci (80–82). This property has been important in radiosensitizing breast cancer cells and esophageal cancer cells (82, 83). Furthermore, it showed synergy with PARP inhibitors to induce cellular apoptosis (80). Also, berberine was able to increase the sensitivity of triple negative breast cancer cells to cisplatin, camptothecin, and methyl methanesulfonate by attenuating XRCC1-mediated repair of base excision and subsequently increasing double-stranded DNA breaks (84).

Genistein is a multifunctional isoflavonoid whose best-known source is soy-based foods. Genistein has been shown to modulate various pathways involved with obesity, metabolic syndrome, and cancer (85). In normal skin, genistein reduces the formation of cyclobutane pyrimidine dimers caused by UVB radiation (86), and in rats treated with genistein, BRCA1 expression was elevated and tumorigenesis caused by 7,12-dimethylbenz [a] anthracene (DMBA) was reduced (87). Genistein inhibited both homologous recombination repair and non-homologous end joining pathway in glioblastoma cells and sarcoma cells after the damage caused by the radiation of carbon ions. This can be explained by considering that genistein prevents the phosphorylation of DNA-PKcs and KU80, and it delays the formation of RAD51 foci (88, 89). The same happened with X-ray therapy and a combined treatment of genistein and IGF1R inhibitor AG1024 in prostate cancer cells (90). Genistein has also been shown to reduce AP-1 levels and sensitize these cells to doxorubicin nanoparticles (91). Interestingly, normal liver cells were protected from damage by ionizing radiation using low concentrations of genistein (92).

Other Compounds
Thymoquinone is the main active component of Nigella sativa Linn seed extracts and has been shown to possess antineoplastic properties. This compound induces DNA damage and apoptosis in glioblastoma cells where shortening of telomeres is involved by a DNA-PKcs-dependent mechanism (93). Honokiol is a biphenolic compound with a powerful antineoplastic activity which is obtained from the Magnolia officinalis plant. It is more toxic in tumor cells than in normal cells and has been reported to inhibit the activity of the X family polymerases (β and λ), affecting the base excision repair pathway and making various cancer cells more susceptible to the effect of bleomycin and temozolomide (94). Ellagic acid obtained from various fruits and vegetables is a polyphenolic compound that can reduce MGMT expression in glioblastoma cells and together with anti-angiogenic therapy with bevacizumab (which also affects DNA repair by reducing the expression of ERCC-1 and XRCC-1) improves the radiosensitivity of tumors (95, 96). Celastrol is a polyphenolic compound isolated mainly from plants in the Celastraceae family. Celastrol has been shown to exhibit significant antioxidant, anti-inflammatory, and antineoplastic activities. For this last aspect, celastrol promotes a reduction in cancer cells of the monoubiquitinated FANCD2 protein, promoting its degradation by the proteasome and affecting the activation of the DNA damage-induced Fanconi anemia pathway and the downstream pathways. Thus, enhancing the effects of crosslinking agents such as cisplatin (97). Cantharidin is a substance of the terpenoid class that is secreted by many species of blister beetles, and which has been observed to sensitize pancreatic cancer cells to the effects of ionizing radiation by increasing levels of phosphorylated H2AX and affecting the expression of UBE2T, RPA1, GTF2H5, LIG1, POLD3, RMI2, XRCC1, PRKDC, FANCI, FAAP100, RAD50, RAD51D, RAD51B, and DMC1, which are important for repair by homologous recombination and non-homologous end joining pathway (98). In bladder cancer cells, decreased phosphorylated ATR and H2AX, as well as total levels of DNA-PK, PARP, MGMT, BRAC1, and MDC1 were observed with this compound (99). Garcinol, a polyisoprenylated benzophenone derivative of the fruit rind Garcinia indica, sensitizes cervical cancer cells to ionizing radiation by inhibiting non-homologous end joining pathway by preventing chromatin remodeling, especially histone acetylation (100, 101). Gastric cancer cells treated with high doses of β-carotene showed a significant decrease in the KU70 and KU80 proteins (102). Androgen receptor-target DNA repair genes were epigenetically repressed in androgen-sensible prostate cells after treatment with 3,3’-diindolylmethane, a compound derived from indole-3-carbinol and found in cruciferous vegetables such as broccoli, brussels sprouts, cabbage, and kale (103). Kaempferol inhibited the expression of DNA-PKcs, MDC1, MGMT, p53, 14-3-3, phosphorylated forms of ATM and ATR in promyelocytic leukemia cells but increased phosphorylated p53 and H2AX. Kaempferol is a flavonoid found in vegetables and fruits such as berries, grapefruit, and Ginkgo biloba (104). Luteolin, a flavonoid enriched in various vegetables and plants such as carrots, broccoli, and parsley, reduced phosphorylation levels of ATM, CHK2, and H2AX in oral squamous cell carcinoma cells (105). In lung squamous carcinoma cells, luteolin caused an increase in the levels of MHT1, OGG1, and AP-1 (106). Withanolide D, a compound obtained from Withania somnifera, was shown to improve the radiosensitivity of different cancer cell lines by inhibiting DNA damage via non-homologous end joining repair pathway (107). Isoorientin is a flavonoid extracted from many plant species, such as flax straw, watery leaf, Gypsophila elegans, Phyllostachys pubescens, Patrinia, and Drosophyllum lusitanicum. Meanwhile, harmine is a tricyclic β-carboline alkaloid that was originally isolated from Peganum harmala seeds. Both compounds inhibited repair by homologous recombination in hepatoma cells, without affecting normal cells, by inhibiting the ATM-downstream signaling pathways and therefore enhancing the effects of ionizing radiation, hydroxyurea, mitomycin C, olaparib, and camptothecin (108, 109). Ferulic acid potentiated the effects of PARP inhibitors on breast cancer cells by reducing the formation of RAD51 foci and lengthening the time that double-stranded DNA breaks remain unrepaired (110). Capsaicin, the main bioactive compound found in chili peppers of the Capsicum genus, downregulates the ERCC1 protein in lung cancer cells by promoting its proteasomal degradation, thereby enhancing the cytotoxic effects of the EGFR inhibitor erlotinib (111, 112). β-Thujaplicin, a natural monoterpenoid found in the wood of trees in the Cupressaceae family, sensitized osteosarcoma cells to damage caused by ionizing radiation, as it inhibits the formation of RAD51 foci and keeps RPA phosphorylated (113). Retiegeric acid B potentiates the effects of cisplatin on hormone-refractory prostate cancer cells by affecting nucleotide excision repair, particularly ERCC1, TFB5, and RPA1 proteins, and mismatch repair, presumably MSH2 and MSH6 proteins (114).

Natural compounds have been be used with other drugs to make cancer cells more sensitive to radiation therapy and different chemotherapeutic agents, even reversing the resistance mechanisms that these cells may have developed. Since increasing the levels of genes involved in DNA repair is a mechanism used by many cancer cells to resist the effects of radio and chemotherapy, the fact that natural compounds can affect the DNA repair pathways makes them candidates to reverse cases of resistance and thus, perhaps contribute to the improvement of patients to allow their survival time to be longer. Despite this potential, there are currently very few clinical trials testing these compounds in combination with chemotherapy or radiotherapy, mainly due to all the challenges that this entails [revised in (115)], including shortages of funds due to lack of patentability and manufacturing difficulties. It is necessary to continue studying different natural compounds and their effects on DNA repair systems in order to implement them in current treatment strategies, establish the appropriate doses and times, and decipher the mechanisms of action by which they carry out their effects.
I am well wisher of everyone! GOD will pardon all your sins but not your Central Nervous System! Think Positive!
Post Reply